| Drug General Information |
| Drug ID |
DX1CLZ
|
| Drug Name |
N-[3-(5-methoxythien-2-yl)-4-oxo-2,4-dihydroindeno[1,2-c]pyrazol-5-yl]-2,2-dimethylhydrazinecarboxamide
|
| Synonyms |
CHEMBL325453
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Formula |
C18H17N5O3S
|
| Canonical SMILES |
COc1ccc(s1)c2[nH]nc3c4cccc(NC(=O)NN(C)C)c4C(=O)c23
|
| InChI |
InChI=1S/C18H17N5O3S/c1-23(2)22-18(25)19-10-6-4-5-9-13(10)17(24)14-15(9)20-21-16(14)11-7-8-12(26-3)27-11/h4-8H,1-3H3,(H,20,21)(H2,19,22,25)
|
| InChIKey |
VWMKXSIQIRRBPL-UHFFFAOYSA-N
|
| Target and Pathway |
| Target(s) |
Cell division protein kinase 4 |
Target Info |
|
[1]
|
|---|
| G1/S-specific cyclin E1 |
Target Info |
|
[1]
|
|
KEGG Pathway
|
Cell cycle
|
|
p53 signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Tight junction
|
|
T cell receptor signaling pathway
|
|
Hepatitis B
|
|
Measles
|
|
HTLV-I infection
|
|
Pathways in cancer
|
|
Viral carcinogenesis
|
|
Pancreatic cancer
|
|
Glioma
|
|
Melanoma
|
|
Bladder cancer
|
|
Chronic myeloid leukemia
|
|
Small cell lung cancer
|
|
Non-small cell lung cancerhsa04110:Cell cycle
|
|
Oocyte meiosis
|
|
MicroRNAs in cancer
|
|
Prostate cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
EGFR1 Signaling Pathway
|
|
RANKL Signaling PathwayNetPath_14:IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Cell cycle
|
|
Parkinson disease
|
|
p53 pathway
|
|
p53 pathway feedback loops 2
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
|
|
Validated targets of C-MYC transcriptional activation
|
|
ATF-2 transcription factor network
|
|
FOXM1 transcription factor network
|
|
Regulation of retinoblastoma proteinprlsignalingeventspathway:Signaling events mediated by PRL
|
|
E2F transcription factor network
|
|
mTOR signaling pathway
|
|
BARD1 signaling events
|
|
PLK3 signaling events
|
|
Regulation of retinoblastoma protein
|
|
Reactome
|
Oxidative Stress Induced Senescence
|
|
Senescence-Associated Secretory Phenotype (SASP)
|
|
Oncogene Induced Senescence
|
|
RMTs methylate histone arginines
|
|
Transcriptional regulation of white adipocyte differentiation
|
|
Ubiquitin-dependent degradation of Cyclin D1
|
|
Cyclin D associated events in G1
|
|
Meiotic recombinationR-HSA-113510:E2F mediated regulation of DNA replication
|
|
G0 and Early G1
|
|
SCF(Skp2)-mediated degradation of p27/p21
|
|
DNA Damage/Telomere Stress Induced Senescence
|
|
Cyclin E associated events during G1/S transition
|
|
G1/S-Specific Transcription
|
|
p53-Dependent G1 DNA Damage Response
|
|
WikiPathways
|
DNA Damage Response
|
|
G1 to S cell cycle control
|
|
Ovarian Infertility Genes
|
|
PPAR Alpha Pathway
|
|
Bladder Cancer
|
|
S Phase
|
|
Transcriptional Regulation of White Adipocyte Differentiation
|
|
Meiotic Recombination
|
|
Retinoblastoma (RB) in Cancer
|
|
Spinal Cord Injury
|
|
Integrated Pancreatic Cancer Pathway
|
|
Prostate Cancer
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
Integrated Breast Cancer Pathway
|
|
Integrated Cancer pathway
|
|
Mitotic G1-G1/S phases
|
|
Cell Cycle
|
|
miRNA Regulation of DNA Damage ResponseWP707:DNA Damage Response
|
|
ID signaling pathway
|
|
Parkinsons Disease Pathway
|
|
Parkin-Ubiquitin Proteasomal System pathway
|
|
miRNAs involved in DNA damage response
|
|
miRNA Regulation of DNA Damage Response
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | URL: https://www.ebi.ac.uk/chembl/ The ChEMBL database in 2017 |
|---|
